california inc pacb-
survey result suggest signific increas util rais pt
invest summari reiter overweight rate rais
pt earlier week conduct person
survey high volum genom center ask end-us smrt
cell expect launch respond plan use pacbio
smrt cell sampl compar respond current
use pacbio sampl significantli analysi
user data suggest mean util pacbio smrt cell
substanti increas share pacbio howev think top-lin
perform may choppi next quarter think custom may
wait smrt cell pt reflect increas confid util
follow survey reflect expect trade rel
premium peer consist cover rel premium
 person question survey result suggest signific increas
util current level respond plan use pacbio
sampl compar respond current use
pacbio sampl interestingli respond
plan use pacbio smrt cell util current
use pacbio util
 analysi respond suggest mean util
pacbio smrt cell use median respond interv
expect util point estim calcul mean util
respons consid respond includ respond
plan adopt mean util signific increas
estim pacbio market share estim
compound-annual-growth-rate next-gen sequenc market point share take
revenu
respond would consid pay premium rel current
price respond would consid pay premium
smrt cell sequel system wherea respond will
consid pay premium smrt cell sequel system
respond would consid pay premium sequel system
smrt cell
disclosur section may found page
pacbio million well chip respond survey remind pacbio plan launch
smrt cell million well zero-mod waveguid pacbio smrt cell run
sequel system enabl long-read sequenc via compani proprietari singl molecul
real-tim smrt technolog provid respond pacbio publish expect
smrt cell includ averag read length base pair output gb
billion base pair hour run time consensu accuraci coverag
impli consum cost per human genom
yesterday oct pacbio releas newest version softwar new consum reagent
new million well smrt cell metric million well smrt cell
releas yesterday million well smrt cell releas shown
exhibit metric pacbio current offer yesterday oct expect
exhibit respond includ current pacbio custom non-pacbio custom
pacbio custom pacbio custom exhibit current util pacbio system human genom sequenc respond
current util respond use pacbio sampl
respond current use pacbio greater sampl view data
consist estim pacbio roughli share market
exhibit expect util pacbio system human genom sequenc given pacb publish
expect smrt cell respond
expect util respond plan use pacbio greater util
human genom sampl respond plan use pacbio greater
util respond plan use pacbio smrt cell util also
current use pacbio sampl current use pacbio
exhibit mean util suggest potenti signific revenu acceler smrt cell
util sampl pacbiong market octob
mean util methodolog use median interv rang respond
includ state previou bar graph point estim respond expect
util use point estim mean expect util respond
ci rel pacbio approxim share sequenc market
signific increas expect util market research end
indic market growth compound-annual-growth-rate estim point share
pacbio repres revenu
next-gener sequenc market base dollar estim sequenc market
use factset consensu sequenc revenu cover
estim market conserv ignor larg sequenc player qgeb
nc user util market growth think signific revenu
acceler pacbio achiev pacbio abil take meaning share may play
number year ultim view recept strong among respond
exhibit willing pay smrt cell sequel rel current price respond
willing pay respond mix qualit willing pay smrt cell
sequel rel current price respond said would will consid
premium wherea respond said would will consid premium
sequel system smrt cell respond said would will pay
premium smrt cell sequel system
responsespoint estimaterespons intervalcontributionno smrt cell sequel smrt cell premiumpremium smrt cell onlypremium sequel onlypremium smrtcell sequel exhibit pacbio role popul sequenc smrt cell respond
role popul sequenc respond feel pacbio nich player
limit util popul sequenc remain respond believ pacbio
play least limit role includ limit role moder role signific role
data geograph limit respond locat us base uk
pacbio larg presenc china revenu asia larg china growth
y/i fuel plant anim sequenc specif crop sequenc think pacbio
may role popul sequenc china addit potenti us may
reflect survey
base price target ev/sal multipl revenu estim
discount back wacc multipl repres premium averag
high-growth small-cap tool diagnost compani valuat methodolog chang
ev/sal ev/sal multipl reflect increas confid
custom util survey result particularli late
current trade ntm sale histor averag think
start demonstr abil take share market multipl trade
rel premium peer similar rel premium trade larg cap tool
diagnost compani price target repres upsid current level
may year away profit capital-intens busi may
requir access capit build toward profit failur gener addit capit may
prevent compani reach profit
next gener sequenc market competit next gener sequenc
market grow rapid pace howev industri leader includ
cover market share market leader larg compani signific
financi resourc could make difficult smaller compani like compet smaller
compani also fight share
visibl busi may limit manag suspend revenu guidanc
highlight lack visibl quarterli cadenc busi instrument sale lumpi
natur therefor forecast futur busi may difficult recogn revenu
instrument placement instal also may difficult predict larg piec
capit equip may requir high level plan laboratori
academ govern fund environ could chang typic sell
instrument academ research institut lab fund govern grant fund
environ chang dramat less commit genom healthcar
gener may advers effect
california
million except per share data
cost good sold
interest expens incom
incom incom tax
compani document cantor fitzgerald research
found base menlo park ca pacif bioscienc california develop manufactur market next-
gener sequenc instrument consum relat servic compani singl molecul real-tim smrt platform
includ pacbio rs ii instrument sequel character offer high consensu accuraci long read length
compani product enabl de novo genom assembl finish genom order fulli identifi annot deciph genom
structur full-length transcript analysi improv annot refer genom character altern splice isoform
find novel gene target sequenc more-comprehens character genet variat dna base modif identif
help character epigenet regul dna damag compani market portfolio integr system consum
analysi tool wide rang custom includ genom research center academ institut govern laboratori hospit
refer laboratori well pharmaceut biotechnolog agbio commerci molecular diagnost compani
price close oct
